Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions.
Abdulrahman Z, Hendriks N, J Kruse A, Somarakis A, J M van de Sande A, J van Beekhuizen H, M J Piek J, de Miranda NFCC, Kooreman LFS, F M Slangen B, van der Burg SH, de Vos van Steenwijk PJ, van Esch EMG. Abdulrahman Z, et al. Among authors: kooreman lfs. J Immunother Cancer. 2022 Nov;10(11):e005288. doi: 10.1136/jitc-2022-005288. J Immunother Cancer. 2022. PMID: 36323430 Free PMC article.
TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial.
Koeneman MM, Kruse AJ, Kooreman LFS, Zur Hausen A, Hopman AHN, Sep SJS, Van Gorp T, Slangen BFM, van Beekhuizen HJ, van de Sande M, Gerestein CG, Nijman HW, Kruitwagen RFPM. Koeneman MM, et al. Among authors: kooreman lfs. BMC Cancer. 2016 Feb 20;16:132. doi: 10.1186/s12885-016-2187-3. BMC Cancer. 2016. PMID: 26897518 Free PMC article. Clinical Trial.
Topical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia (TOPIC-3): A Nonrandomized Multicenter Study.
Hendriks N, Koeneman MM, van de Sande AJM, Penders CGJ, Piek JMJ, Kooreman LFS, van Kuijk SMJ, Hoosemans L, Sep SJS, de Vos Van Steenwijk PJ, van Beekhuizen HJ, Slangen BFM, Nijman HW, Kruitwagen RFPM, Kruse AJ. Hendriks N, et al. Among authors: kooreman lfs. J Immunother. 2022 Apr 1;45(3):180-186. doi: 10.1097/CJI.0000000000000414. J Immunother. 2022. PMID: 35180719 Free PMC article. Clinical Trial.
Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma.
Hendrikse CSE, van der Ploeg P, van de Kruis NMA, Wilting JHC, Oosterkamp F, Theelen PMM, Lok CAR, de Hullu JA, Smedts HPM, Vos MC, Pijlman BM, Kooreman LFS, Bulten J, Lentjes-Beer MHFM, Bosch SL, van de Stolpe A, Lambrechts S, Bekkers RLM, Piek JMJ. Hendrikse CSE, et al. Among authors: kooreman lfs. Cancer. 2023 May 1;129(9):1361-1371. doi: 10.1002/cncr.34661. Epub 2023 Mar 3. Cancer. 2023. PMID: 36867576 Free article.
Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.
van Wagensveld L, van Baal JOAM, Timmermans M, Gaillard D, Borghuis L, Coffelt SB, Rosenberg EH, Lok CAR, Nijman HW, Kooreman LFS, Sanders J, de Bruijn M, Wessels LFA, van der Wiel R, Rausch C, Broeks A, Kruitwagen RFPM, van der Aa MA, Sonke GS, Schouten PC, Van de Vijver KK, Horlings HM. van Wagensveld L, et al. Among authors: kooreman lfs. Cancers (Basel). 2022 Dec 2;14(23):5965. doi: 10.3390/cancers14235965. Cancers (Basel). 2022. PMID: 36497449 Free PMC article.
59 results